. 2022 Mar 22;11(7):1063. doi: 10.3390/cells11071063

Table 2.

The main demographic and biochemical characteristics of the subjects.

Characteristic		All Patients			Gout Patients			Hyperuricemia Patients			p-Value
		(N = 150)			(N = 114)			(N = 36)			#
		N	%		N	%		N	%
Gender	Male	121	80.7		100	87.7		21	58.3		0.0004
	Female	29	19.3		14	12.3		15	41.7		0.0004
Familial occurrence		42	28		35	30.7		7	19.4		0.2097
Familial occurrence		42	(29 *)		35	30.7		7	(22.6 *)		0.2097
Characteristic		N	Median	Range	N	Median	Range	N	Median	Range	p -Value
Characteristic		N	(IQR)	Range	N	(IQR)	Range	N	(IQR)	Range	†
Age at examination [years]		150	59	3–80	114	59	30–80	36	55.5	3–78	0.13335
Age at examination [years]		150	21	3–80	114	19	30–80	36	34.3	3–78	0.13335
BMI at examination		108	29.1	16–43.4	80	29	20.6–43.4	28	30.1	16–37.5	0.7391
BMI at examination		108	5.3	16–43.4	80	5.4	20.6–43.4	28	5.1	16–37.5	0.7391
Gout/hyperuricemia onset [years]		125	45	13–77	112	45	18–77	13	48	13–70	0.4025
Gout/hyperuricemia onset [years]		125	23	13–77	112	21.3	18–77	13	36	13–70	0.4025
SUA at examination, with medication [µmol/L, (mg/dL)]		137	373(6.2)	163–725 (2.7–12.1)	107	371(6.2)	163–725 (2.7–12.1)	30	411(6.9)	240–628 (4.0–10.5)	0.1197
SUA at examination, with medication [µmol/L, (mg/dL)]		137	123(2.1)	163–725 (2.7–12.1)	107	118(1.9)	163–725 (2.7–12.1)	30	155.3(2.5)	240–628 (4.0–10.5)	0.1197
FEUA at examination, with medication		135	3.4	0.9–11.8	107	3.4	0.9–11.8	28	3.5	1.3–8.4	0.974
FEUA at examination, with medication		135	2.1	0.9–11.8	107	2	0.9–11.8	28	2.2	1.3–8.4	0.974

# Fisher’s exact test (significance level: 0.05). † Wilcoxon rank-sum test (significance level: 0.005). * relative frequencies when missing information about familial occurrence was excluded. IQR = interquartile range; BMI = body mass index; SUA = serum urid acid; FEUA = fractional excretion of urid acid.